BIOLASE (BIOL) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock BIOL vs. LGMK, BLAC, BJDX, NAOV, DYNT, BBLG, NUWE, TTOO, IONM, and HSDTShould you be buying BIOLASE stock or one of its competitors? The main competitors of BIOLASE include LogicMark (LGMK), Bellevue Life Sciences Acquisition (BLAC), Bluejay Diagnostics (BJDX), Nanovibronix (NAOV), Dynatronics (DYNT), Bone Biologics (BBLG), Nuwellis (NUWE), T2 Biosystems (TTOO), Assure (IONM), and Helius Medical Technologies (HSDT). These companies are all part of the "medical equipment" industry. BIOLASE vs. Its Competitors LogicMark Bellevue Life Sciences Acquisition Bluejay Diagnostics Nanovibronix Dynatronics Bone Biologics Nuwellis T2 Biosystems Assure Helius Medical Technologies BIOLASE (NASDAQ:BIOL) and LogicMark (NASDAQ:LGMK) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings. Which has better valuation & earnings, BIOL or LGMK? LogicMark has lower revenue, but higher earnings than BIOLASE. LogicMark is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBIOLASE$48.83M0.00-$20.63M-$14.94N/ALogicMark$9.88M0.22-$14.55M-$223.500.00 Is BIOL or LGMK more profitable? BIOLASE has a net margin of -41.65% compared to LogicMark's net margin of -141.96%. LogicMark's return on equity of -124.91% beat BIOLASE's return on equity.Company Net Margins Return on Equity Return on Assets BIOLASE-41.65% -1,782.73% -55.31% LogicMark -141.96%-124.91%-92.05% Do institutionals & insiders hold more shares of BIOL or LGMK? 8.8% of BIOLASE shares are held by institutional investors. Comparatively, 7.9% of LogicMark shares are held by institutional investors. 0.3% of BIOLASE shares are held by company insiders. Comparatively, 2.2% of LogicMark shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts rate BIOL or LGMK? BIOLASE presently has a consensus price target of $1.20, suggesting a potential upside of 0.00%. Given BIOLASE's stronger consensus rating and higher probable upside, equities research analysts clearly believe BIOLASE is more favorable than LogicMark.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00LogicMark 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, BIOL or LGMK? BIOLASE has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, LogicMark has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Does the media prefer BIOL or LGMK? In the previous week, LogicMark had 5 more articles in the media than BIOLASE. MarketBeat recorded 5 mentions for LogicMark and 0 mentions for BIOLASE. LogicMark's average media sentiment score of 0.90 beat BIOLASE's score of 0.00 indicating that LogicMark is being referred to more favorably in the news media. Company Overall Sentiment BIOLASE Neutral LogicMark Positive SummaryBIOLASE beats LogicMark on 8 of the 15 factors compared between the two stocks. Get BIOLASE News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIOL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIOL vs. The Competition Export to ExcelMetricBIOLASEDental equipment & supplies IndustryMedical SectorNASDAQ ExchangeMarket Cap$581K$14K$5.76B$9.65BDividend YieldN/AN/A3.91%4.09%P/E Ratio0.00N/A30.7825.12Price / SalesN/A0.00457.76157.42Price / CashN/AN/A25.2228.45Price / BookN/A0.009.365.94Net Income-$20.63M-$60.92M$3.26B$265.56M BIOLASE Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIOLBIOLASE0.9039 of 5 starsN/A$1.20+∞N/A$581K$48.83M0.00160LGMKLogicMark0.452 of 5 stars$0.00-9.3%N/A-99.9%$2.25M$9.88M0.0020News CoverageGap UpBLACBellevue Life Sciences AcquisitionN/A$0.53+1.6%N/A-95.1%$2.14MN/A0.00N/AGap UpHigh Trading VolumeBJDXBluejay Diagnostics0.625 of 5 stars$1.39+2.2%N/A-89.6%$2.03M$250K-0.019News CoverageShort Interest ↑Gap UpNAOVNanovibronix0.1308 of 5 stars$6.35+8.4%N/A-90.6%$1.52M$2.66M-0.4720Earnings ReportGap UpDYNTDynatronicsN/A$0.10-2.9%N/A-42.9%$1.28M$33.60M-0.12200Gap DownHigh Trading VolumeBBLGBone Biologics1.0162 of 5 stars$2.08-5.5%N/A-76.9%$1.20MN/A0.002Earnings ReportShort Interest ↓NUWENuwellis1.6357 of 5 stars$6.30+13.7%N/A-91.9%$580K$8.74M-0.1870News CoverageEarnings ReportShort Interest ↓Gap DownHigh Trading VolumeTTOOT2 BiosystemsN/A$0.01-45.0%N/A-99.7%$463K$7.68M0.00180Positive NewsGap DownIONMAssureN/A$0.05flatN/A-84.4%$150K$149K0.00130News CoverageHSDTHelius Medical Technologies0.6968 of 5 stars$6.43+6.6%N/A-98.8%$80K$520K0.0030News CoveragePositive NewsEarnings ReportAnalyst UpgradeShort Interest ↑ Related Companies and Tools Related Companies LogicMark Alternatives Bellevue Life Sciences Acquisition Alternatives Bluejay Diagnostics Alternatives Nanovibronix Alternatives Dynatronics Alternatives Bone Biologics Alternatives Nuwellis Alternatives T2 Biosystems Alternatives Assure Alternatives Helius Medical Technologies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIOL) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BIOLASE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BIOLASE With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access